Annual Report from Cyxone AB for the period 1 January 2019 to 31 December 2019

Cyxone AB’s Annual Report for the financial year 2019 is now available at the company’s website (www.cyxone.com).

Please see attached Annual Report as pdf.

Contact
Ola Skanung, interim CEO & CFO
Tel: +46 (0) 705 121 040
Email: ola.skanung@cyxone.com 
Adelgatan 21
211 22 Malmö
www.cyxone.com

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se. www.cyxone.com